Stelara (Ustekinumab) Denied: How to Appeal Psoriasis, Crohn's, and UC Denials

Stelara (ustekinumab) is an IL-12/23 inhibitor FDA-approved for plaque psoriasis, psoriatic arthritis, moderate-to-severe Crohn's disease, and moderately to severely active ulcerative colitis. It has been a cornerstone biologic across gastroenterology and dermatology for over a decade. Now with ustekinumab biosimilars entering the US market — including Wezlana, Otulfi, and others — patients on stable Stelara therapy face a new wave of non-medical switching pressure. Here is how to navigate both new and existing Stelara denials.

Why Stelara Is Denied

TNF-failure prerequisite for IBD. For Crohn's disease and ulcerative colitis, nearly every commercial insurer requires prior failure of at least one TNF inhibitor (adalimumab or infliximab) before approving Stelara. This is a step therapy requirement that goes beyond the FDA label — the label approves Stelara for moderate-to-severe Crohn's regardless of prior biologic history. If your gastroenterologist recommends Stelara first-line for safety reasons (prior malignancy, high infection risk, demyelinating disease), that clinical rationale must be clearly documented.

Psoriasis step therapy. For psoriasis and psoriatic arthritis, insurers typically require failure of methotrexate, cyclosporine, or acitretin before approving a biologic. Some plans also require prior failure of a TNF inhibitor before an IL-12/23 inhibitor will be approved.

Biosimilar forced switching. Ustekinumab biosimilars became available in 2024, and insurers have rapidly moved to make biosimilars preferred or to remove brand Stelara from formulary. Patients who have been stable on Stelara for years are being told they must switch. This is non-medical switching and is subject to appeal and state law protections in many jurisdictions.

Dose and interval disputes. Stelara dosing for Crohn's is weight-based IV induction followed by subcutaneous maintenance. Insurers occasionally deny the IV induction dose by routing it under the wrong benefit (pharmacy vs. medical), or dispute the Q8W vs. Q12W maintenance interval. Document your prescriber's rationale for the specific dosing schedule used.

Appealing TNF-Failure Requirements

If your gastroenterologist is recommending Stelara without prior TNF therapy, your appeal must address why step therapy should be bypassed:

• Prior TNF exposure and failure: If you tried a TNF inhibitor (adalimumab, infliximab, certolizumab) and failed due to primary non-response, secondary loss of response, or adverse events, document these specifically. Serious adverse events like demyelination, lupus-like syndrome, or new-onset heart failure from TNF inhibitors provide strong bypass grounds.
• Safety contraindications to TNF therapy: Documented history of demyelinating disease, prior lymphoma, or high risk of serious infection from TNF inhibitors supports bypassing to Stelara.
• Fistulizing Crohn's: If TNF failure documentation exists for fistulizing disease, the clinical urgency argument is particularly strong.

Addressing Biosimilar Switching

For patients being pushed off brand Stelara to a biosimilar, the appeal strategy has several layers:

Review your state's non-medical switching laws. Multiple states have enacted protections preventing insurers from forcing mid-therapy switches to biosimilars or lower-tier drugs without clinical justification. If you are in a state with such protections and you are stable on brand Stelara, your insurer may be required to continue coverage.

Document clinical stability and risk of immunogenicity. Switching between ustekinumab reference product and biosimilar introduces the theoretical risk of immunogenicity — development of anti-drug antibodies that reduce the drug's effectiveness. While this risk is debated in the literature, your prescriber can document clinical concerns about switching a stable patient as grounds for continued brand coverage.

Request continuity of care exception. If you were recently started on brand Stelara and are mid-induction, request a continuity-of-care exception to complete induction on the prescribed product before any formulary change is imposed.

Documentation Checklist for Stelara Appeal

• Diagnosis and FDA indication (specify: psoriasis, PsA, CD, or UC)
• Severity scoring (PASI/BSA for psoriasis; CDAI/HBI/endoscopy for Crohn's; Mayo score for UC)
• Prior treatment history (conventional and biologic therapies, dates, doses, outcomes)
• Prescriber letter explaining why Stelara is appropriate for this patient specifically
• Relevant lab work (CRP, fecal calprotectin, albumin, CBC)
• Clinical notes from most recent visit documenting active disease

Fight Back With ClaimBack

Stelara denials — whether for a new prescription or a biosimilar switch dispute — require precise documentation of your clinical situation and clear knowledge of your appeal rights. ClaimBack builds that appeal for you.

Start your Stelara appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• Internal vs. External Insurance Appeal: What's the Difference?
• Common Reasons Insurance Claims Are Denied